Latest Capital Raise News

Nagambie Resources has successfully raised $600,000 through a placement of 60 million shares, accompanied by free attaching options, to fund its strategic antimony-gold project at Nagambie Mine.

Excite Technology Services Limited reported a remarkable 370% revenue increase to $13.54 million for H1 FY2026, driven by strong growth across its cybersecurity, digital forensics, and IT managed services divisions. However, losses widened 43% to $2.51 million, reflecting restructuring and scaling costs, while the company secured $2.1 million in convertible notes to support its growth ambitions.

Galilee Energy has voluntarily suspended its shares from trading as it finalises a significant capital raising and acquisition, with an announcement expected by 1 December 2025.

ikeGPS Group reports a robust first half of FY26 with subscription revenue surging 47%, driven by AI innovation and strong market demand. The company reaffirms its FY26 growth targets amid a solid balance sheet and leadership expansion.

BTC Health has raised $2 million through a share placement priced at a slight premium, with director Martin Kahanovitz participating and a new South African investor joining the register.

Ryzon Materials Ltd has lodged a prospectus to raise up to $10 million through a share placement with free-attaching options, aiming to meet ASX conditions for lifting its securities suspension and advancing its Nachu graphite project.

L1 Group Limited has successfully closed its Share Purchase Plan, raising the targeted $25 million despite demand exceeding $31.9 million. The company will issue over 26 million new shares, with scaled allocations to balance shareholder equity.

VHM Limited has launched a non-underwritten Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to invest up to $30,000 at $0.35 per share, a significant discount to recent trading prices. The capital raised will support key development stages of the Goschen Project ahead of a final investment decision in early 2026.

Platinum Capital Limited’s 2025 AGM marked a pivotal shift as shareholders approved replacing Platinum Investment Management with L1 Capital, aiming to revive the company’s challenged investment performance.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

VEEM Limited reported a year of consolidation in FY25 with solid second-half growth driven by new defence contracts and the promising launch of its VEEM Extreme propulsion system. Despite a revenue dip, the company is poised for a stronger FY26 backed by strategic US defence partnerships and product innovation.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.